BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/30/2017 6:51:09 AM | Browse: 1327 | Download: 2028
 |
Received |
|
2017-02-10 12:04 |
 |
Peer-Review Started |
|
2017-02-15 11:31 |
 |
To Make the First Decision |
|
2017-03-08 09:46 |
 |
Return for Revision |
|
2017-03-10 17:30 |
 |
Revised |
|
2017-03-30 21:56 |
 |
Second Decision |
|
2017-05-08 15:23 |
 |
Accepted by Journal Editor-in-Chief |
|
2017-05-08 16:10 |
 |
Accepted by Executive Editor-in-Chief |
|
2017-05-15 05:49 |
 |
Articles in Press |
|
2017-05-15 05:49 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2017-06-29 01:03 |
 |
Publish the Manuscript Online |
|
2017-06-30 06:51 |
ISSN |
2220-6124 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Urology & Nephrology |
Manuscript Type |
Basic Study |
Article Title |
Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease
|
Manuscript Source |
Invited Manuscript |
All Author List |
William E Sweeney, Philip Frost and Ellis D Avner |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
the PKD research program is provided by the Children’s Research Institute, the Lillian Goldman Charitable Trust, Ellsworth Family and Children’s Foundation of Children’s Hospital and Health System of Wisconsin |
|
|
Corresponding Author |
Ellis D Avner, MD, Emeritus Professor of Pediatrics and Physiology, Founding Director, Children’s Research Institute, Children’s’ Hospital Health System of Wisconsin and the Medical College of Wisconsin, Medical College of Wisconsin, Suite C-510, Mailstop CCC C510, 999 North 92nd Street, Milwaukee, WI 53226, United States. bsweeney@mcw.edu |
Key Words |
Autosomal recessive; Autosomal dominant; Polycystic kidney disease; Therapy; Kinase inhibition; Multi-kinase inhibitor; Phosphorylation; Renal cysts; Biliary; G-protein coupled receptor |
Core Tip |
This study examined the effect of a multi-kinase inhibitor, tesevatinib (TSV) on cyst development and growth in rodent models of autosomal recessive polycystic kidney disease (ARPKD). Tesevatinib which targets epidermal growth factor receptors, Src and KDR is currently in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) and given the molecular and cellular interactions of the ADPKD and ARPKD genes and proteins we sought to determine if TSV would ameliorate ARPKD in two well described models and an orthologous rat model of ARPKD phenocopy. Of particular interest was the effect of TSV’s inhibition of VEGFR2 or KDR during early post-natal development and renal maturation. |
Publish Date |
2017-06-30 06:51 |
Citation |
Sweeney WE, Frost P, Avner ED. Tesevatinib ameliorates pro¬gression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 2017; 6(4): 188-200 |
URL |
http://www.wjgnet.com/2220-6124/full/v6/i4/188.htm |
DOI |
http://dx.doi.org/10.5527/wjn.v6.i4.188 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345